Paxlovid and molnupiravir were approved in Aotearoa early in 2022 for treating COVID-19 in adults at increased risk of progressing to severe disease, hospitalisation or death. Variations in the dispensing of these medicines suggest inequitable access. Read this microlearning to find out more.

Gout services vary between regions and populations but one common factor is that success requires a whole-of-team approach. This article introduces the online Gout Guide, a helpful local resource that draws on a range of experience and proven tools to help improve gout outcomes.

This video is a recording of the live webinar hosted by Mobile Health on 14 March 2024. Professor Nicola Dalbeth provides a clinical update on gout and information about new resources for health providers to support effective gout management.

All RA-Morph oral liquid strengths are now out of stock or expired. Wockhardt 10mg/5ml (2mg/ml) and Oramorph 2mg/ml are available instead (both are Section 29 medicines) but supply gaps may occur during April.

Read this article for important points to note. 

The most commonly used maintenance dose of allopurinol is 300mg daily, but this dose may not reduce serum urate enough to suppress gout flares. Find out more about appropriate allopurinol dosing in this microlearning. 

To date, two oral antiviral agents have been approved in Aotearoa New Zealand for treating COVID-19 in adults who are at increased risk of progressing to severe disease, hospitalisation or death. This article reports on the uptake of these medicines between April 2022 and December 2023, based on dispensing data provided by Te Whatu Ora.

Chronic hepatitis C can cause cirrhosis, liver failure, cancer and early death. Raising awareness that hep C can be cured with a short course of oral antivirals is vital. Read this microlearning to find out more.